Infirst Healthcare has revealed that Granulox is currently available on the National Health Service (NHS) Drug Tariff Part IX for UK patients suffering from non-healing wounds.
The Granulox haemoglobin spray is said to increase oxygen levels at the wound bed, therefore increasing healing and reducing pain.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Infirst Healthcare CEO Manfred Scheske said: “This is very good news for UK patients who suffer from debilitating chronic wounds that severely affect their physical and emotional well-being.
“It is also good news for healthcare professionals and for the NHS to add a novel treatment option to standard therapy that promises significant patient benefits, as well as cost effectiveness.”
Nearly 200,000 patients in the UK are currently living with non-healing wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcers and post-surgical wounds.
More than 80% of the wounds are associated with venous insufficiency, high blood pressure or diabetes mellitus, leading to inadequate oxygen supply via the vascular system.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataNHS spends up to £3.1 billion annually on treating such chronic wounds.
The costs associated with treating these patients include nursing time, dressings, hospital admissions, pain relief and frequent amputations.
Date from independent clinical studies revealed that, when added to standard care, Granulox could save the NHS an average of £2,330 for every diabetic foot ulcer patient and £1,469 for every chronic wound patient after six months.
The clinical efficacy and cost analysis data have also been reviewed and verified by the Scottish Health Technologies Group (SHTG), part of NHS Scotland.
